Candriam S.C.A. Arcus Biosciences, Inc. Transaction History
Candriam S.C.A.
- $18.4 Billion
- Q3 2025
A detailed history of Candriam S.C.A. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 378,441 shares of RCUS stock, worth $7.31 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
378,441Holding current value
$7.31 Million% of portfolio
0.03%Shares
6 transactions
Others Institutions Holding RCUS
# of Institutions
213Shares Held
67.7MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$189 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.63MShares$128 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$115 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$77.2 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$71.2 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.39B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...